Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.67 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22288352 | 0.87 | P2RX7 (0.61) | P2RX7AHRKMT2AMEN1BRD4 | |
| SCHEMBL29362265 | 0.87 | P2RX7 (0.61) | P2RX7AHRKMT2AMEN1BRD4 | |
| Hydrochloric Acid SCHEMBL30601969 | 0.85 | P2RX7 (0.59) | P2RX7AHRKMT2AMEN1BRD4 | |
| Oxalic Acid SCHEMBL30601976 | 0.83 | P2RX7 (0.56) | P2RX7AHRKMT2AMEN1BRD4 | |
| SCHEMBL1412900 | 0.82 | P2RX7 (0.69) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL30601973 | 0.81 | P2RX7 (0.54) | P2RX7AHRKMT2AMEN1SNCA | |
| Sulfuric Acid SCHEMBL30601991 | 0.81 | P2RX7 (0.54) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL109491 | 0.80 | P2RX7 (1.00) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL20905297 | 0.79 | P2RX7 (0.61) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL22290176 | 0.79 | P2RX7 (0.66) | P2RX7AHRKMT2AMEN1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794912-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2024-03-29 | — | — | CN | claimed |
| US-20240059671-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-02-22 | — | — | US | claimed |
| CN-117377669-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-117321043-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117242072-A | TYK2 inhibitor and application thereof | 苏多生物科学有限公司 | 2023-12-15 | — | — | CN | claimed |
| WO-2023213308-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 苏州隆博泰药业有限公司 | 2023-11-09 | — | — | WO | claimed |
| CN-111936486-B | Heterocyclic compounds comprising pyridine as modulators of IL-12, IL-23 and/or IFN alpha responses | 百时美施贵宝公司 | 2023-09-22 | — | — | CN | claimed |
| CN-111936486-A | Pyridine-containing heterocyclic compounds useful as modulators of IL-12, IL-23, and/or IFN alpha response | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | claimed |
| CN-102015716-A | Imidazo [1,2-b] pyridazine derivatives for the treatment of C-MET tyrosine kinase mediated disease | NOVARTIS AG | 2011-04-13 | — | — | CN | claimed |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LTD (GB) | 2026-02-26 | — | — | US | disclosed |
| US-20250179022-A1 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | SHANGHAI ZHIGEN PHARMACEUTICAL & TECHNOLOGY CO. LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-120040441-A | Compositions and methods for treating cancer | A2A制药有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119522217-A | Compositions and methods for treating cancer | A2A制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119317622-A | Compounds useful as TYK2 inhibitors, preparation method and application thereof in medicine | 上海致根医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-111936486-A | Pyridine-containing heterocyclic compounds useful as modulators of IL-12, IL-23, and/or IFN alpha response | 百时美施贵宝公司 | 2020-11-13 | — | — | CN | disclosed |
| CN-104884454-B | The heterocyclic compound of acid amides substitution as IL 12, IL 23 and/or IFN α answer-reply regulator | 百时美施贵宝公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-104781252-B | Alkyl-amide substituted pyridine compounds useful as IL-12, IL-23 and/or IFN alpha response modulators | 百时美施贵宝公司 | 2017-11-17 | — | — | CN | disclosed |
| CN-102015716-A | Imidazo [1,2-b] pyridazine derivatives for the treatment of C-MET tyrosine kinase mediated disease | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2291371-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179022-A1 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | TYK2, WEE2, WEE1 | P2RX7 3417/4885AHR 1044/4885KMT2A 276/4885 |
| US-20240059671-A1 | TYROSINE KINASE 2 (TYK2) DEGRADATION COMPOUNDS AND METHODS OF USE | TYK2, ERBB2, PTK2B | P2RX7 3943/4885AHR 1216/4885KMT2A 560/4885 |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, CSNK2A3, CSNK2B | P2RX7 4340/4885AHR 797/4885KMT2A 390/4885 |
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | P2RX7 356/4885AHR 200/4885KMT2A 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.